Search

Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease

Boehringer Ingelheim Statement on ATS/ERS/JRS/ALAT Guidelines for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

Boehringer Ingelheim welcomes the new guidance issued by American Thoracic Society, European Respiratory Society, Japanese Respiratory Society and Asociación Latinoamericana de Tórax for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis • K

J-Code Issued for SPEVIGO

Boehringer Ingelheim receives permanent J-code for SPEVIGO, indicated for the treatment of generalized pustular psoriasis flares in adults

Yankees Legend Bernie Williams Teams Up With Multi-Platinum Recording Artist and Actress Jordin Sparks to Unveil New Song Featuring Lyrics From The Breathless® Ballad Challenge Winner

USDA & BI Expand Research Opportunities | Boehringer Ingelheim US

Find out more about how veterinary students will work with USDA scientists in researching emerging diseases related to both animal and public health.

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials

FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

Asthmatic Horse's First Inhaled Therapy | Boehringer Ingelheim US

Click here to read about Boehringer Ingelheim launching the first inhaled therapy for horses suffering with severe asthma in the United States.

BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

FDA Grants BTD for Investigational Treatment of CIAS | BI US

Learn about the breakthrough therapy designation grant for BI's latest investigational treatment of cognitive impairment associated with schizophrenia.

Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark

Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis

US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

FDA accepts sNDA for children/adolescents with fibrosing ILD

U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

Boehringer welcomes 2023 Gold Report

Boehringer welcomes 2023 GOLD Report Positioning LAMA/LABA as preferred treatment

Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Phase III study showed Ofev slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial

Boehringer Ingelheim announces nintedanib expanded access program (EAP) for children and adolescents with fibrosing interstitial lung disease

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease

Boehringer Ingelheim Statement on ATS/ERS/JRS/ALAT Guidelines for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

J-Code Issued for SPEVIGO

Yankees Legend Bernie Williams Teams Up With Multi-Platinum Recording Artist and Actress Jordin Sparks to Unveil New Song Featuring Lyrics From The Breathless® Ballad Challenge Winner

USDA & BI Expand Research Opportunities | Boehringer Ingelheim US

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Boehringer Ingelheim refocuses PDE9 inhibition brain research on schizophrenia following results from Phase II Alzheimer’s trials

FDA Advisory Committee Recommends Approval of Ofev® for the Treatment of Systemic Sclerosis Associated ILD

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

Asthmatic Horse's First Inhaled Therapy | Boehringer Ingelheim US

BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR

Boehringer Ingelheim to Acquire NBE-Therapeutics for EUR 1.18 Billion, Significantly Enhancing Its Cancer Pipeline Portfolio with Novel Antibody-Drug Conjugates

FDA Grants BTD for Investigational Treatment of CIAS | BI US

Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark

Biosimilar Cyltezo® demonstrates clinical equivalence to Humira® in patients with moderate-to-severe plaque psoriasis

US FDA approves Jardiance® (empagliflozin) to treat adults living with heart failure with reduced ejection fraction

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

FDA accepts sNDA for children/adolescents with fibrosing ILD

FDA approves the first treatment option for generalized pustular psoriasis flares in adults

Boehringer welcomes 2023 Gold Report

Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial

Boehringer Ingelheim announces nintedanib expanded access program (EAP) for children and adolescents with fibrosing interstitial lung disease